RxDoctor Payments Data

Dylan Lovin, MD

Internal Medicine · Charlotte, NCNPI 1518385053

Payments from drug & device makers

$754in general payments, 2019–2025

Across 24 payments — averaging $31.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$439
  • Mylan Specialty L.p.$39
  • Insmed, Inc.$38
  • Merck$34
  • AstraZeneca$31
  • Boehringer Ingelheim$30
  • plus $144 from 7 others

What the payments were for

  • Food & beverage$70593%
  • Education$507%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$754 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$66,752
Medicare patients
188
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate18$208,649
Trelegy ElliptaFluticasone/Umeclidin/Vilanter181$130,280
Spiriva RespimatTiotropium Bromide19$14,799
SymbicortBudesonide/Formoterol Fumarate34$13,151
Pirfenidone12$9,134
Breo ElliptaFluticasone/Vilanterol17$7,419
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$6,987
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$4,720
Wixela InhubFluticasone Propion/Salmeterol33$3,757
Albuterol Sulfate HfaAlbuterol Sulfate102$3,456
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$3,267
Ventolin HfaAlbuterol Sulfate15$1,358
Prednisone69$271
Montelukast Sodium18$211
Doxycycline Hyclate17$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$30$223,44837 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$20$144,686214 claims
AstraZenecaSymbicort$31$13,15134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →